Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 1079-1082

  Cui, Longzhu ^a   Tominaga, Eiji ^a   Neoh, Hui Min ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; CORRELATION ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CELL WALL; DAPTOMYCIN; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 33644655658     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.1079-1082.2006     Document Type: Article

References (20)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Akins, R. L., and M. J. Rybak. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. 44:1925-1929.
3. Alder, J. 2005. Daptomycin: a new drug class for the treatment of Gram-positive infections. Drugs Today (Barcelona) 41:81-90.
4. Cetinkaya, Y., P. Falk, and C. G. Mayhall. 2000. Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 13:686-707.
5. Cha, R., R. G. Grucz, Jr., and M. J. Rybak. 2003. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 47:1598-1603.
6. Cui, L., and K. Hiramatsu. 2003. Vancomycin-resistant Staphylococcus aureus, p. 187-212. In A. C. Fluit and F. J. Schmitz (ed.), MRSA: current perspectives. Caister Academic Press, Norfolk, England.
7. Cui, L., A. Iwamoto, J.-Q. Lian, H.-M. Neoh, T. Maruyama, Y. Horikawa, and K. Hiramatsu. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.
8. Cui, L., J. Lian, H. Neoh, R. Ethel, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3404-3413.
9. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
10. Cui, L., H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285.
11. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
12. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
13. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:486-493.
14. Hiramatsu, K., L. Cui, and K. Kuwahara-Arai. 2004. Has vancomycin-resistant Staphylococcus aureus started going it alone? Lancet 364:565-566.
15. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J. Antimicrob. Chemother. 40:135-136.
16. Laganas, V., J. Alder, and J. A. Silverman. 2003. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob. Agents Chemother. 47:2682-2684.
17. Mangili, A., I. Bica, D. Snydman, and D. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.
18. Petersen, P., P. Bradford, W. Weiss, T. Murphy, P. Sum, and S. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
19. Schriever, C., C. Fernandez, K. Rodvold, and L. Danziger. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158.
20. Tally, F., M. Zeckel, M. Wasilewski, C. Carini, C. Berman, G. Drusano, and F. B. J. Oleson. 1999. Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs 8:1223-1238.